Martin is an Independent Director on the Board of Praesidia. He is also the Co-founder and Chief Executive Officer of Context Therapeutics and has been advising Praesidia since 2020. In addition, Martin serves on the board of CureDuchenne Ventures. Previously, he was part of the founding team at Osage University Partners, a venture capital fund focused on academic spinouts from leading research institutions. Prior to Osage University Partners, Martin conducted research at the Sloan Kettering Institute in DNA repair and at the Children’s Hospital of Philadelphia in thrombosis and hemostasis. Martin is a director of BioBreak, a biotech executive peer networking group with over 2,500 active members across the United States, and an advisory board member of Life Science Cares and Life Science Leader magazine. He holds an M.A. in Biotechnology from Columbia University and a B.A. in Economics from the University of Pennsylvania.

< Back to leadership